Crystalline forms of N[4[4-(4-Morpholinyl)-7H-Pyrrolo[2-3-D]Pyrimidin-6-yl]Phenyl]-4-[[3(R)-[(1-Oxo-2-Protein-1-yl)Amino]-1-Piperidinyl]Methyl]2-Pyridinecarboxamide]

US12215113B2 · kind B2 · utility

Assignee

• BIOMEA FUSION, INC. · US

Inventors

• Satish Puppali · Rancho Cucamonga, US
• James T. Palmer · San Ramon, US
• Thorsten A. Kirschberg · Mountain View, US
• Angelina Sau Man Wong · Redwood City, US
• Heow Tan · Cupertino, US
• Jay Li · Franklin, US
• Jing-Jer Lin · Redwood City, US
• Ming Gao · Saskatoon, CA
• Junlu Ding · Shanghai, CN
• Shuang Li · Tianjin, CN
• Yuyao GU · Shanghai, CN
• Hongyan He · Shanghai, CN
• Bo Zheng · Sunnyvale, US
• Yanjing Zhou · Shanghai, CN
• Mei You · Shanghai, CN

Key dates

• Filing date: Jan 30, 2024
• Grant date: Feb 4, 2025
• Expiry date: Jan 30, 2044

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide (Compound A) (Formula I),